TABLE 1.
Baseline characteristics of 7 SOT recipients who had COVID-19 infection after SARS-COV-2 mRNA vaccination
| Patient | Organ | Age | Gender | Race | Blood type | Cause of organ failure | Previous organ Tx | Induction IS | Maintenance IS | Rejection history | Years from Tx to COVID-19 | Vaccine name | Number of doses | Days from last vaccine dose to COVID-19 diagnosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Double Lung | 64 | M | C | A | COPD | No | ATG | Bela/Pred/MMF | Yes | 7.37 | Pfizer/BioNTech | 2 | 35 |
| 2 | Heart/Kidney | 68 | M | C | A | ICM/FSGS | No | ATG | Tac/MMF/Pred | No | 3.21 | Pfizer/BioNTech | 2 | 26 |
| 3 | Kidney | 60 | M | AA | A | DM | No | Alemtuzumab | Tac/MMF/Pred | No | 1.3 | Moderna | 2 | 44 |
| 4 | Kidney | 42 | M | AA | O | HIVAN | Yes | ATG | Tac/MMF/Pred | No | 0.58 | Pfizer/BioNTech | 1 | 6 |
| 5 | Kidney Pancreas | 43 | M | C | A | DM | No | ATG | Tac/MMF/Pred | Yes | 11.35 | Moderna | 1 | 28 |
| 6 | Heart | 69 | M | C | AB | ICM | No | Basiliximab | Tac/MMF/Pred | No | 0.85 | Pfizer/BioNTech | 2 | 6 |
| 7 | Heart | 67 | M | C | A | NICM | No | Basiliximab | Tac/MMF/Pred | No | 0.58 | Moderna | 2 | 19 |
Abbreviations: AA, African American; ATG, antithymocyte globulin; Bela, Belatacept; C, Caucasian; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HIVAN, HIV associated nephropathy; ICM, ischemic cardiomyopathy; IS, immunosuppression; M, male; MMF, mycophenolate mofetil; NICM, nonischemic cardiomyopathy; Pred, prednisone; Tac, Tacrolimus.